In today’s session DexCom, Inc. (DXCM) recorded an unusually high (227) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious DXCM decrease. With 227 contracts traded and 224 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: DXCM161118P00065000 closed last at: $4.6 or 557.1% up. About 733,668 shares traded hands. DexCom, Inc. (NASDAQ:DXCM) has declined 14.77% since April 4, 2016 and is downtrending. It has underperformed by 15.86% the S&P500.
DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage
Out of 12 analysts covering Dexcom (NASDAQ:DXCM), 11 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 92% are positive. $120 is the highest target while $70 is the lowest. The $90.88 average target is 46.44% above today’s ($62.06) stock price. Dexcom has been the topic of 18 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Neutral” rating by BTIG Research on Wednesday, September 14. As per Wednesday, February 24, the company rating was maintained by JP Morgan. Deutsche Bank maintained the shares of DXCM in a report on Friday, July 15 with “Buy” rating. The stock has “Buy” rating given by Benchmark on Wednesday, February 24. Piper Jaffray maintained DexCom, Inc. (NASDAQ:DXCM) rating on Friday, August 7. Piper Jaffray has “Buy” rating and $103 price target. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Neutral” rating by Robert W. Baird on Monday, February 8. The firm has “Buy” rating given on Wednesday, November 2 by Canaccord Genuity. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Buy” rating given on Friday, September 16 by Desjardins Securities. The firm earned “Buy” rating on Wednesday, February 24 by Jefferies. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Overweight” rating by Morgan Stanley on Monday, November 2.
According to Zacks Investment Research, “Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes.”
Insitutional Activity: The institutional sentiment increased to 1.35 in Q2 2016. Its up 0.40, from 0.95 in 2016Q1. The ratio improved, as 30 funds sold all DexCom, Inc. shares owned while 77 reduced positions. 46 funds bought stakes while 98 increased positions. They now own 82.43 million shares or 5.55% more from 78.09 million shares in 2016Q1.
Wfg Advsrs L P, a Texas-based fund reported 1 shares. Macquarie Gru Limited accumulated 0.03% or 221,340 shares. The Connecticut-based Point72 Asset Lp has invested 0.14% in DexCom, Inc. (NASDAQ:DXCM). Stifel Fincl Corp, a Missouri-based fund reported 20,315 shares. Security Trust Comm has 0.07% invested in the company for 2,268 shares. Moreover, Nationwide Fund Advisors has 0.06% invested in DexCom, Inc. (NASDAQ:DXCM) for 179,126 shares. Winfield Assocs, a Ohio-based fund reported 5 shares. Tocqueville Asset Mgmt Lp, a New York-based fund reported 21,695 shares. Eagle Asset Mgmt Inc holds 136,859 shares or 0.08% of its portfolio. Great West Life Assurance Com Can owns 93,170 shares or 0.02% of their US portfolio. State Bank Of America Corp De accumulated 678,889 shares or 0.01% of the stock. Moreover, Cupps Mngmt Lc has 1.43% invested in DexCom, Inc. (NASDAQ:DXCM) for 69,756 shares. Moreover, Loomis Sayles L P has 0.01% invested in DexCom, Inc. (NASDAQ:DXCM) for 68,133 shares. Proshare Advsr Limited Liability Co has 2,765 shares for 0% of their US portfolio. Cormorant Asset Mngmt Ltd has 100,000 shares for 1.12% of their US portfolio.
Insider Transactions: Since May 9, 2016, the stock had 0 insider purchases, and 67 selling transactions for $61.41 million net activity. The insider Balo Andrew K sold $464,366. The insider LISTER JOHN sold $282,494. Another trade for 4,557 shares valued at $364,560 was made by MOY JEFFREY on Wednesday, June 29. Shares for $239,500 were sold by ROPER JESS. 18,239 shares with value of $1.29 million were sold by Pacelli Steven Robert on Wednesday, June 8. $927,151 worth of DexCom, Inc. (NASDAQ:DXCM) shares were sold by GREGG TERRANCE H. 1,674 shares were sold by DOUBLEDAY RICHARD, worth $106,446 on Monday, May 23.
Dexcom, Inc. is a medical device company. The company has a market cap of $5.21 billion. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. It currently has negative earnings. The Company’s products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
DXCM Company Profile
Dexcom, Inc. (Dexcom), incorporated on May 13, 1999, is a medical device company. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. The Company’s products consist of SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The Firm had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system in the European Union, Australia, New Zealand and the countries in Asia and Latin America.
More news for DexCom, Inc. (NASDAQ:DXCM) were recently published by: Fool.com, which released: “Here’s Why DexCom, Inc. Is Plunging Today” on November 02, 2016. Businesswire.com‘s article titled: “DexCom, Inc. Reports Third Quarter 2016 Financial Results” and published on November 01, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.